Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 461-469

  Li, Qiao ^b   Furman, Senta A ^b   Bradford, Carol R ^b   Chang, Alfred E ^a,b  

^a 3302 Cancer Center ^*  (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPH NODES; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHENOTYPE;

EID: 0033016871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49: 281-355, 1991.
2. Rosenberg, S. A., Spiess, P., and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (Washington DC), 233: 1318-1321, 1986.
3. Yoshizawa, H., Chang, A. E., and Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol., 147: 729-737, 1991.
4. Geiger, J. D., Wagner, P. D., Cameron, M. J., Shu, S., and Chang, A. E. Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother., 13: 153-165, 1993.
5. Goedegebuure, P. S., Zuber, M., Leonard-Vidai, D. L., Burger, U. L., Cusack, J. C., Jr., Chang, M. P., Douville, L. M., and Eberlein, T. J. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is association with in vivo efficacy. Ann. Surg. Oncol., 3: 79-89, 1994.
6. Chang, A. E., Aruga, A., Cameron, M. J., Sondak, V. K., Normolle, D. P., Fox, B. A., and Shu, S. Adoptive immunotherapy with vaccineprimed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol., 15: 796-807, 1997.
7. June, C. H., Ledbetter, J. A., Linsley, P. S., and Thompson, C. B. Role of the CD28 receptor in T-cell activation. Immunol. Today, 11: 211-216, 1990.
8. Chirmule, N., McCloskey, T. W., Hu, R., Kalyanaraman, V. S., and Pahwa S. HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B7-1). J. Immunol., 155: 917-924, 1995.
9. Blankson, J. N., and Morse S. S. The CD28/B7 pathway costimulates the response of primary murine T cells to superantigens as well as to conventional antigens. Cell. Immunol., 157: 306-312, 1994.
10. Dubey, C., Croft, M., and Swain, S. L. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J. Immunol., 157: 3280-3289, 1996.
11. + T cells. J. Exp. Med., 179: 1539-1549, 1994.
12. Chang, A. E., Sondak, V. K., Bishop, D. K., Nickoloff, B. J., Mulligan, R. C., and Mulé, J. J. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with GM-CSF gene. Hum. Gene Ther., 7: 773-792, 1996.
13. + murine splenic T cells. Transplant, 61: 486-491, 1996.
14. + allergen-specific T-cell clones from programmed cell death. Allergy, 50: 677-682, 1995.
15. + T cells in the absence of exogenous feeder cells. J. Immunol., 159: 5921-5930, 1997.
16. Ohteki, T., and MacDonald, H. R. Expression of the CD28 costimulatory molecule on subsets of murine intestinal intraepithelial lymphocytes correlates with lineage and responsiveness. Eur. J. Immunol., 23: 1251-1255, 1993.
17. Asjo, B., Cefal, D., Debré, P., Dudoit, Y., and Autran B. A novel mode of human immunodeficiency virus type 1 (HIV-1) activation: ligation of CD28 alone induces HIV-1 replication in naturally infected lymphocytes. J. Virol., 67: 4395-4398, 1993.
18. + T lymphocytes. Eur. J. Immunol., 26: 2299-2303, 1996.
19. + tumor-draining lymph node cells involved in mediating tumor regression. J. Leukocyte Biol., 61: 507-516, 1997.
20. Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K., and Chang, A. E. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity. J. Immunol., 159: 664-673, 1997.
21. + cell subsets during T cell activation. Immunol. Methods, 173: 27-31, 1994.
22. + cells are genetically restricted effectors and their production requires CD4 and I-A expression. Int. Arch. Allergy Immunol., 109: 334-343, 1996.
23. + T lymphocytes and human squamous cell carcinoma of the head and neck. Cell. Immunol., 177: 35-48, 1997.
24. + T-helper and a T-killer cell. Nature (Lond.), 393: 474-478, 1998.
25. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J., and Heath, W. R. Help for cytotoxic T cell responses is mediated by CD40 signalling. Nature (Lond.), 393: 478-480, 1998.
26. Schoenberger, S. P., Toes, R. E., van der Voort, E., Offringa, R., and Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (Lond.), 393: 480-483, 1998.
27. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer, 58: 69-79, 1994.
28. Rosenberg, S. A. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu. Rev. Med., 47: 481-491, 1996.
29. Halder, T., Pawelec, G., Kirkin, A. F., Zeuthen, J., Meyer, H. E., Kun, L., and Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res., 57: 3238-3244, 1997.
30. + HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens. Int. J. Cancer, 72: 403-407, 1997.
31. + early progenitor cells. Blood, 90: 1083-1090, 1997.
32. Miyazaki, A., Sato, N., Takahashi, S., Sasaki, A., Kohama, G., Yamaguchi, A., Yagihashi, A., and Kikuchi, K. Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4 killer T cells against human autologous squamous cell carcinoma. Jpn. J. Cancer Res., 88: 191-197, 1997.
33. Boon, T., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
34. Gaugler, B., Brouwenstijn, N., Vantomme, V., Szikor, J. P., Van der Spek, C. W., Patard, J. J., Boon, T., Schrier, P., and Van den Eynde, B. J. A new gene coding for an antigen recognized by autologous cytolic T lymphocytes on a human renal carcinoma. Immunogenetics, 44: 323-330, 1996.
35. Brändle, D., Basseur, F., Weynants, P., Boon, T., and Van den Eynde, B. J. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med., 183: 2501-2508, 1996.
36. Rubin, J. T., Elwood, L. J., Rosenberg, S. A., and Lotze, M. T. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res., 49: 7086-7092, 1989.
37. Cameron, R. B., McIntosh, J. K., and Rosenberg, S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res., 48: 5810-5817, 1988.